Quick Answer
Methylfolate Mood Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Introduction Emerging real-world evidence suggests that folate supplementation may reduce suicidal ideation and behavior.
Key Takeaways
- 01Introduction Emerging real-world evidence suggests that folate supplementation may reduce suicidal ideation and behavior. [Noel C (2026)]
- 02One within-person cohort study found a 44% lower hazard of suicide-related emergency or hospital visits after treatment with folic acid (hazard ratio = 0.56) (and none in a parallel analysis of vitamin B12). [Noel C (2026)]
- 03One case-control study of patients with a history of suicidal behavior and ideation found lower suicidal ideation questionnaire scores with folinic acid ( P Discussion Evidence linking folate supplementation to reduced suicidal behavior is promising but limited by heterogeneity in design, sample size, folate formulation, and outcome measurement. [Noel C (2026)]
- 04We conducted a scoping review to evaluate current hypothesis-testing literature on folate supplementation and outcomes related to suicide. [Noel C (2026)]
The current Migaku evidence database contains 2 reusable source documents for Methylfolate Mood Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Introduction Emerging real-world evidence suggests that folate supplementation may reduce suicidal ideation and behavior. [Noel C (2026); evidence level 3]
- One within-person cohort study found a 44% lower hazard of suicide-related emergency or hospital visits after treatment with folic acid (hazard ratio = 0.56) (and none in a parallel analysis of vitamin B12). [Noel C (2026); evidence level 3]
- One case-control study of patients with a history of suicidal behavior and ideation found lower suicidal ideation questionnaire scores with folinic acid ( P Discussion Evidence linking folate supplementation to reduced suicidal behavior is promising but limited by heterogeneity in design, sample size, folate formulation, and outcome measurement. [Noel C (2026); evidence level 3]
- We conducted a scoping review to evaluate current hypothesis-testing literature on folate supplementation and outcomes related to suicide. [Noel C (2026); evidence level 3]
- A comprehensive review of psychiatric presentations reported that psychiatric symptoms span attention problems, anxiety, mood/behavioral disorders, and psychosis and identified > 100 IEMs associated with psychiatric manifestations; in a curated analysis, 94 IEMs were linked to psychiatric symptoms, with mood changes ranging from depressive syndromes to bipolar-like presentations []. [Hachmeriyan Antoniya (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources